Company Overview
About Be Biopharma
Be Biopharma uses CRISPR to engineer a patient's own B cells into continuous protein-secreting factories — a one-time treatment designed to replace lifelong enzyme replacement therapy for rare metabolic diseases. The company has raised $274 million in total financing including a $92 million Series C co-led by Nextech Invest and Bristol Myers Squibb, with ARCH Venture Partners as a continuing investor, and has an active Phase 1/2 trial (BeCoMe-9) for BE-101 in Hemophilia B.
Business Model & Competitive Advantage
B cells are uniquely suited for this approach: they naturally produce antibodies in large quantities, are long-lived in vivo, and can be engineered ex vivo without the viral vector constraints of other gene therapy approaches. By replacing the B cell's antibody-producing program with a therapeutic protein payload via CRISPR, Be Bio creates a personalized, long-duration protein delivery system that the patient's own immune architecture sustains.
Competitive Landscape 2025–2026
Bristol Myers Squibb's co-investment is the most significant commercial signal: BMS has one of the world's largest rare disease and hematology portfolios, and its investment thesis is likely rooted in the platform's potential to replace BMS's existing enzyme replacement therapy products with a one-time cure approach. Hemophilia B data from the Phase 1/2 trial in 2026 will be the first human validation of engineered B cell protein secretion durability.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Be Biopharma is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Be Biopharma has achieved $274M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Be Biopharma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Be Biopharma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Be Biopharma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Be Biopharma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →